Fulgent Genetics (FLGT) Equity Ratio (2015 - 2026)

Fulgent Genetics has disclosed Equity Ratio across 12 years of filings, most recently posting 0.9 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.9, down 3.03% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.9 (down 3.03% YoY), and the FY2025 annual result was 0.92, down 1.0% from the prior year.
• Equity Ratio came in at 0.9 for Q1 2026 at Fulgent Genetics, down from 0.92 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 13.62 in Q4 2022 to a low of 0.9 in Q1 2022.
• The 5-year median for Equity Ratio is 0.92 (2024), against an average of 1.66.
• Across the five-year window, Equity Ratio surged 1393.89% in 2022 and plunged 93.26% in 2023, its largest moves.
• Fulgent Genetics' Equity Ratio stood at 13.62 in 2022, then slumped by 93.26% to 0.92 in 2023, then gained by 0.89% to 0.93 in 2024, then declined by 1.0% to 0.92 in 2025, then slipped by 1.46% to 0.9 in 2026.
• The last three Equity Ratio figures came in at 0.9 (Q1 2026), 0.92 (Q4 2025), and 0.92 (Q3 2025), per Business Quant data.